Partnership takes Heart Pacing technology to new level – Labmate Online
SpeciSafe® All-in-One Secondary Packaging Solution Makes Compliant Biol…
Bovine pneumonia test supports on-farm interpretation approach
Applications of Raman Spectroscopy
PEEK HPLC Column Hardware
Challenges of Lab Data Management
Why is Nitrosamine Analysis Important in Pharmaceuticals?
Jan 01 2023
MedTech company Ceryx Medical has partnered with Berlin-based Osypka Medical to develop a heart device which, through real-time modulation, is set to change the way patients with heart failure and other cardiac conditions are treated. Its bionic device Cyson, prompts the heart to beat in line with the patient’s breathing, listening and responding to the body, rather than triggering the strict metronomic beats that current pacemakers do.
Ceryx’s CEO, Dr Stuart Plant, said, “It’s a huge breakthrough in the treatment of people with even the most serious heart conditions. Our studies show that Cysoni increases cardiac output by at least 20% when compared with monotonic pacing while at the same time it enables heart cells to repair themselves. This is a ground-breaking development for patients with conditions such as heart failure, who will have the opportunity to live longer, fuller lives.”
The partnership will result in the combination of the Welsh MedTech company’s device with Osypka Medical’s pacemaker for the purpose of in-human testing. This clinical study is scheduled to take place in the 3rd quarter of 2023 and will take Ceryx closer to commercialising its technology.
Dr Plant explained, “Osypka is a world leader in cardiac pacing technologies and is well-known for their innovation in the development and manufacturing of medical devices, it’s great that their team has shown such enthusiasm for our product. We’re hopeful that a longer-term partnership will emerge from this, which sees Cysoni becoming a standard part of pacemaking technology.”
Dr Markus Osypka, President and CEO of Osypka Medical said “We believe in hemodynamically optimised pacing therapy. Ceryx’s Cysoni technology has the potential to become another quantum leap in pacing therapy very much like A-V synchronous pacing is today, but without placing the additional burden on the operator.”
The clinical trials, which will take place in the UK and New Zealand, will involve heart failure patients who have undergone a coronary artery bypass being fitted with this external device. These patients are usually paced for just a few hours after surgery, but the Ceryx team plans to extend this in order to build a full picture of Cysoni’s capabilities.
“All of our data so far points to Cysoni being capable of doing things no other pacing device has been able to do,” said Dr Plant. It’s the result of ground-breaking research at the Universities of Bath and Bristol. The technology has also undergone five years of rigorous laboratory testing and pre-clinical evaluations as part of our collaboration with the University of Auckland in New Zealand. This next step, in partnership with Osypka, takes us within touching distance of making Cysoni available to the global healthcare community.”
Last year Ceryx Medical received a Business Start-up Award from the Institute of Physics (IOP) and was the winner of an Innovation Award from Mediwales.
More information online
Social enterprise Global Access Diagnostics (GADx) has joined a collaboration that will take forward the development of RaDiCal, a one-step molecular lateral…
Dec 31 2022
Animal health provision-focused Enalees, a company specialising in the design, development, production and marketing of rapid molecular diagnostic tests and…
Dec 31 2022
A second round equity investment of £487k towards the end of 2022, is enabling University of Birmingham spin-out ChromaTwist Ltd to continue development of…
Dec 30 2022
Registration for the Solutions in Science (SinS) conference and exhibition is now open and early bird rates are available. This meeting brings together exper…
Dec 23 2022
December 2022
In This Edition Chromatography – Optimising Viral Vector Purification Strategies with Multimodal Chromatography – Key UHPLC Characteristics Required for High throughput LC-MS – New Low Volu…
Smart Factory Expo 2023
Jan 25 2023 Tokyo, Japan
Arab Health
Jan 30 2023 Dubai, UAE
Nano Tech 2023
Feb 01 2023 Tokyo, Japan
Medlab Middle East
Feb 06 2023 Dubai, UAE
FILTECH
Feb 14 2023 Cologne, Germany
International Labmate Limited
Oak Court Business Centre
Sandridge Park, Porters Wood
St Albans
Hertfordshire
AL3 6PH
United Kingdom
T +44 (0)1727 858 840
F +44 (0)1727 840 310
E info@labmate-online.com
Copyright © 2023 Labmate Online. All rights reserved.